October 2015 | OncologyLive

Nanotechnology May Lead to Tumor-Priming Strategy in Pancreatic Cancer

November 03, 2015

Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but also could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.

Cancer Drugs Drive Costs Beyond Forecasts in 340B Discount Program

October 31, 2015

The discount drug program intended for safety-net hospitals and special AIDS clinics has mushroomed even more than earlier reports have suggested, with oncology drugs fueling much of the growth, according to a new report commissioned by community oncology providers.

Standardization Is Key to Future of "Chemotherapy Bath"

October 30, 2015

A combination of cytoreductive surgical resection and hyperthermic intraperitoneal chemotherapy-sometimes referred to as "hot chemotherapy bath"-has the potential to provide some patients with long-term survival.

Debating the Merits of New Therapeutic Stars in NSCLC

October 29, 2015

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

Personalizing Cancer Drugs: The Next Front in Diagnostics

October 28, 2015

Less than a decade after the FDA set the ground rules for developing assays that pair molecular targets with new drugs, experts say there have been strides in personalizing anticancer therapies but that many hurdles remain before next-generation sequencing and other precision medicine advances are incorporated into the diagnostic paradigm.

Evidence Builds for Multigene Testing for Hereditary Cancers

October 20, 2015

The use of multigene assays to screen patients for hereditary breast and ovarian cancer risk yields clinically valuable information beyond single-gene BRCA testing, but confusion about accurately interpreting the results presents a challenge for clinicians even as panel testing becomes more widely adopted.

Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer

October 15, 2015

The evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.